

**CERTIFICATE OF FILING**

I hereby certify that this paper and every paper referred to therein as being enclosed is being filed with the USPTO electronically via EFS-Web or via first class mail addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below

Date: October 6, 2010

By /Jennifer Archer/  
Jennifer Archer

Docket No. 106985-4 KGB  
Confirmation No. 8817

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT : Alexander STEINKASSERER  
SERIAL NO. : 10/535,522  
CUSTOMER NO. : 27384  
FILED : April 13, 2006  
FOR : USE OF SOLUBLE FORMS OF CD83 AND NUCLEIC ACIDS  
ENCODING THEM FOR THE TREATMENT OR PREVENTION  
OF DISEASES  
ART UNIT : 1644  
EXAMINER : Amy E. Juedes

---

October 6, 2010

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO/SB/08.

**I. Timeliness, Fees and Certifications in lieu of Fees**

This information disclosure statement is being filed after the mailing of a final office action or a notice of allowance, but on or before the payment of the issue fee. Pursuant to 37 CFR § 1.97(d), consideration of this information disclosure statement requires a petition, which

Applicants hereby request, and payment of the petition fee, which is set forth in 37 CFR § 1.17(i), and which the Commissioner is hereby authorized to charge to Deposit Account No. 14-1263. Consideration of this information disclosure statement also requires a statement under 37 CFR § 1.97(e):

Applicants hereby state that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR § 1.56 more than three months prior to the filing of this information disclosure statement.

## **II. Copies of Listed References**

Copies of all references listed on the attached Form PTO Form SB 08 are being supplied. Copies of U.S. patents are not included pursuant to 37 CFR § 1.98 (a) (2) (ii).

## **III. Concise Statement of Relevance**

All references listed on the attached Form PTO Form SB 08 are in the English language, and, therefore, a concise statement of relevance is not required.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

By /Kurt G. Briscoe/

Kurt G. Briscoe  
Attorney for Applicant(s)  
Reg. No. 33,141  
875 Third Avenue - 8<sup>th</sup> Floor  
New York, New York 10022  
Phone: (212) 808-0700  
Fax: (212) 808-0844